Prognostic factors in canine appendicular osteosarcoma – a meta-analysis

Ilse Boerman1, Gayathri T Selvarajah2, Mirjam Nielen3 and Jolle Kirpensteijn1*

Abstract

Background: Appendicular osteosarcoma is the most common malignant primary canine bone tumor. When treated by amputation or tumor removal alone, median survival times (MST) do not exceed 5 months, with the majority of dogs suffering from metastatic disease. This period can be extended with adequate local intervention and adjuvant chemotherapy, which has become common practice. Several prognostic factors have been reported in many different studies, e.g. age, breed, weight, sex, neuter status, location of tumor, serum alkaline phosphatase (SALP), bone alkaline phosphatase (BALP), infection, percentage of bone length affected, histological grade or histological subtype of tumor. Most of these factors are, however, only reported as confounding factors in larger studies. Insight in truly significant prognostic factors at time of diagnosis may contribute to tailoring adjuvant therapy for individual dogs suffering from osteosarcoma. The objective of this study was to systematically review the prognostic factors that are described for canine appendicular osteosarcoma and validate their scientific importance.

Results: A literature review was performed on selected studies and eligible data were extracted. Meta-analyses were done for two of the three selected possible prognostic factors (SALP and location), looking at both survival time (ST) and disease free interval (DFI). The third factor (age) was studied in a qualitative manner. Both elevated SALP level and the (proximal) humerus as location of the primary tumor are significant negative prognostic factors for both ST and DFI in dogs with appendicular osteosarcoma. Increasing age was associated with shorter ST and DFI, however, was not statistically significant because information of this factor was available in only a limited number of papers.

Conclusions: Elevated SALP and proximal humeral location are significant negative prognosticators for canine osteosarcoma.

Keywords: Bone tumor, Dog, Survival, Disease-free interval, Prognostic factors

Background

Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid. OS accounts for approximately 85% of all primary canine bone tumors and is almost exclusively observed in large or giant breeds [1-5]. There is anecdotal evidence suggesting that males are more predisposed. The median age of onset of clinical signs ranges from 8 to 10 years [5,6], although it also occurs in younger dogs [7].

Dogs are often presented with a history of lameness or in some cases with a pathologic fracture of the affected bone. Predilection sites are the weight-bearing regions of the long bones (humerus, femur, radius, tibia and ulna) [8] with approximately 25% of tumors arising in the axial skeleton including the flat bones of the skull, ribs, vertebrae, sternum, and pelvis [9,10]. OS is an aggressive and invasive neoplasm that causes local skeletal destruction and resulting in radiographic evidence of both osteoproducive and osteolytic lesions. They are highly metastatic, predominantly to the lungs with a lower frequency of spread to distant bones, regional lymph nodes [11] and other soft tissues [12,13]. A clinical diagnosis is made following assessment of case signalment and history and based on the radiographic appearance of the
lesion. The definitive diagnosis is currently obtained by histological examination with tumor classification based on the formation of osteoid matrix with osteoblastic, fibroblastic, chondroblastic, telangiectic and combined subtypes [14,15]. There can be considerable variation in the histological appearance both between and within individual neoplasms, however, rendering histological parameters less reproducible between studies.

Dogs with OS that were treated by amputation alone have poor overall survival outcome: median overall survival times are typically less than five months, with the majority suffering from metastatic disease [5,16,17]. Over the years, advances in disease management, including ‘limb-sparing’ surgical and radioablative methods used only to selectively eradicate tumors located in the distal radius, ulna and tibia have been described [18,19]. Adjuvant therapy, such as multimodal chemotherapy regimes, treatment with bisphosphonates or immune modulators and palliative radiation, can also be provided and are reported to improve clinical or survival outcome [20-23]. Combination of therapy modalities and drugs may contribute significantly to survival statistics but randomized, double-blinded studies have not been performed routinely.

There are many well-documented prognostic indicators for canine OS, and the majority of these are similar to those reported from large retrospective studies on human OS, including tumor location, histologic grade, certain biomarkers, the use of chemotherapy, etc. [24-27]. The accurate segregation of canine patients into distinct prognostic subgroups based on such indicators is essential in the tailoring of appropriate treatment. However, the required information is not always completely available in the existing literature and studies report sometimes conflicting results. In this paper, we perform a meta-analysis to estimate the combined effect size over a number of studies of a selection of well-described prognosticators.

The aims of the current study were to systematically review the prognostic factors that are described for canine appendicular osteosarcoma and validate their scientific importance. After validation, a meta-analysis was performed on serum alkaline phosphatase (SALP), tumor location and age at diagnosis to study the association of these factors with survival time (ST) and disease free interval (DFI).

**Materials and methods**

**Search strategy and quality assessment**

A search was performed using Medline (PubMed) and Google Scholar search for all eligible studies performed between January 1970 and May 2011. The following search strategies were applied: [“canine”, “osteosarcoma” and “prognosis”] and [“canine”, “osteosarcoma” and “survival”]. Reports were selected and carefully reviewed that included canine stage <2B appendicular osteosarcoma cases [18]. Additionally, all manuscripts were evaluated for methodological quality according to a standardized questionnaire adapted from Bramer et al. (2009) including variables such as institute where the study was performed, year of publication, number of cases reported (at least 5), whether the study was randomized or not, study design, recorded survival end points, univariate (uva) or multivariate analysis (mva), use of control groups, listing of research period, completeness of follow up information, method of follow up examination, listing if cases were lost to follow up, definition of prognostic factors, listing of therapy modalities and listing of confounding factors. Two independent reviewers (JK, GS) performed study selection, assessment of methodological quality and data extraction. A third reviewer (IB) resolved disagreements, if necessary.

**Statistical analysis**

Studies fulfilling one or two types of quality criteria were selected for meta-analysis. First, only randomized double-blind studies with multivariate data analysis were selected. After that, non-randomized, prospective studies were added to evaluate if additional significant factors could be determined. Studies with similar dog populations, outcome variables, prognostic factors, follow-up information, and adjustment for confounding variables were combined. Adjusted relative risks were pooled with a random effects model and assessed for statistical heterogeneity by Chi-square analysis. After establishment of heterogeneity, the source was determined by meta-analysis.

All meta-analyses were performed using commercial statistical software (Comprehensive meta-analysis V2, ©2006 Biostat, Inc., Englewood, NJ, USA), which provides a table with relative risk for each study and a forest plot. Both binary and continuous data were reported in the selected papers. It was impossible to combine both types of data in the same analysis; therefore for each variable separate sub analyses were performed on the effect measures hazard ratio (HR), median survival time (MST) and median disease free interval (MDFI). The groups compared for the variables SALP and location were as follows: elevated SALP versus SALP within reference range at time of diagnosis; (proximal) humerus compared to other locations in the appendicular skeleton. For age it was not possible to make two groups with the available data; factor data were analysed in a qualitative manner.

Some studies reported univariate data analysis while others reported multivariate data analysis, meaning that a studied factor was corrected for therapy or other confounding factors analysed. Where possible, data of multivariate analysis were used. Where necessary, a (set of) paper(s) was excluded to see if the overall effect changed.
For all meta-analyses performed in this study the random-effects model was used, assuming that the true study effect varies across studies and the observed study effects reflect both this variation and random variation. Selected studies that did not present the data in sufficient detail were qualitatively summarized where necessary.

Results
Inclusion of papers
Through the searches, 821 papers were selected for review of which 55 met the criteria to be included in the study presented here (Additional file 1). No disagreements needed to be resolved by the third reviewer. Of the 55 studies, 16 were multicenter, and 39 monocenter, of which the majority came from Colorado State University (17), Utrecht University (5), University of Wisconsin-Madison and Tufts University (each 4). One study contained two independent studies and was split in two (Kurzman et al., 1995). One study was published in the 1970s, 5 in the 1980s, 14 in the 1990s and 35 in 2000–2011. 14 Studies were considered randomized, 27 studies were prospective, and 29 retrospective. Of all the studies, only 5 were placebo controlled. The number of cases varied from 11 to 303, with a mean of 61 ± 8. Outcome variables included survival time in 51, disease free interval in 32, metastasis free interval (MFI) in 13, and recurrence free interval (RFI) in 6 studies. Univariate analyses were performed in all studies varying from Kaplan Meier (KM) survival curves in 34, KM combined with (Cox) regression analysis in 20, and one study mentioned an ANOVA. Multivariate analysis was performed with a multivariate cox proportional hazard analysis in 18 and some other multivariate test in 7 reports. Historic control groups are common (n = 19) and some studies did not use a control group at all. The time of evaluation after the procedure and methodology varied too but most studies evaluated the dogs every 2–3 months using pulmonary radiography (n = 37); 13 studies did not include any information about follow up techniques. Most studies failed to include how long these dogs needed to be followed up (n = 39) or how many cases were lost to follow up (n = 33). An abundance of treatments were described, of which amputation combined with some kind of chemotherapy was most common.

Significant factors
Many significant factors are described in the 55 papers selected, e.g. age, breed, weight, sex, neuter status, location of tumor, SALP, bone alkaline phosphatase (BAP), infection, percentage of bone length affected, histological grade or histological subtype of tumor. The effect of SALP level, location (proximal humerus) and age at diagnosis were reported most often in the 55 selected papers and these factors were subjected to meta-analyses.

Thirteen papers were included in the meta-analysis on SALP and seven papers in the meta-analysis on (proximal) humerus; some studies reported more than one variable. For age it turned out to be difficult to find sufficient studies with comparable selections of age categories to run meta-analysis on, therefore in the results a qualitative summation is given for all relevant age data found. Six papers reported the effect of age as confounding factor using HR, MST or MDFI, three papers did not give an estimate of the effect size, but only reported a p-value (Additional file 1: Table S1).

Serum alkaline phosphatase
Survival time
For the meta-analysis for SALP on survival time using hazard ratios, data from seven studies were available. Six of these studies used univariate analysis and one used multivariate analysis. All studies combined, the meta-analysis (Figure 1) on hazard ratios showed that dogs with an elevated SALP level at time of diagnosis have shorter survival times compared with dogs with a SALP level within reference range, with a hazard ratio of 1.62 (95 % CI: 1.21–2.17). Leaving the one study with the multivariate analysis (Phillips et al., 2009) out, the hazard ratio dropped to 1.44 (95 % CI: 1.11–1.87). The sub-analysis with median survival times (also seven studies) showed that dogs with elevated SALP overall lived 156 days shorter (MST: -156) compared with dogs with SALP within reference range (95 % CI: -209 to –104) (Figure 2). When selecting only the studies with multivariate or univariate analysis the difference became -132 days (95 % CI: -252 to -11) and –186 days (95 % CI: -248 to –124), respectively.

Disease free interval
For the meta-analysis on disease-free interval ten papers were used, of which the majority was also used for the meta-analysis on survival time. The effect direction of elevated SALP on DFI was comparable to that on ST. Figure 3 shows an overall HR of 1.96 (95 % CI: 1.50–2.56) for dogs with an elevated SALP level at time of diagnosis. The two multivariate analyses (Sotnik et al., 2010 and Phillips et al., 2009) together give a HR of 2.33 (95 % CI: 1.60–3.39) for elevated SALP level. Combining only the univariate analyses, the HR dropped to 1.64 (95 % CI: 1.12–2.40). The difference in MDFI (here only univariate analyses were available) was –123 days (95 % CI: -166 to –79) (Figure 4).

Location - (proximal) humerus
Survival time
Four papers were used for the meta-analysis on ST for location. Of these papers, one reported the humerus as a whole as reference (Kow et al., 2008), the other three
reported the proximal humerus in particular. Analysis on all studies combined (Figure 5) showed that dogs with the primary tumor located in their (proximal) humerus had shorter survival times than dogs with the primary tumor located elsewhere in their appendicular skeleton (HR 1.86; 95 % CI: 1.34–2.57). We also performed subset analyses on three subgroups (mva, uva and proximal humerus) and found no large differences in effect between the subgroups; estimates for HR varied between 1.82 and 2.21. The sub analysis on MST (Figure 6, all manuscripts reporting uva) showed that for (proximal) humerus the MST is 132 days shorter compared with other locations (95 % CI: -211 to −52). Approximately the same difference in MST (−131 days) applied for the sub analysis leaving out the proximal humerus.

**Disease Free Interval**

For the meta-analysis on DFI for location, data from six papers were used, three of which were also used for the analyses on ST. The effect of (proximal) humerus as location on DFI was comparable with the effect on ST. Dogs with primary tumors located in the (proximal) humerus had shorter DFIs compared with other locations (HR 2.53; 95 % CI: 1.34–4.77) (Figure 7). The effect of the proximal humerus in particular was comparable (HR 2.57; 95 % CI: 0.90–7.35). Performing the subanalysis on five papers reporting MDFI (only uva) the overall

| Study name      | Sample size | Hazard ratio | Lower limit | Upper limit | Z-Value | p-Value | Hazard ratio and 95% CI | Relative weight | Relative weight |
|-----------------|-------------|--------------|-------------|-------------|---------|---------|----------------------------|-----------------|----------------|
| Saam 2010(uva)  | 63          | 0.900        | 0.437       | 1.854       | -0.286  | 0.775   | 1.86 (1.34–2.57)          | 11.12           |                |
| Selvarajah 2009(uva) | 32         | 2.439        | 1.094       | 5.438       | 2.179   | 0.029   |                            | 9.62            |                |
| Philips 2009(mva) | 138        | 2.270        | 1.437       | 3.586       | 3.513   | 0.000   |                            | 18.68           |                |
| Tham 2008(uva)  | 21          | 1.660        | 0.481       | 5.728       | 0.802   | 0.423   |                            | 4.82            |                |
| Kow 2008(uva)   | 67          | 2.160        | 1.003       | 4.651       | 1.968   | 0.049   |                            | 10.25           |                |
| Kirpensteijn 2002(uva) | 99      | 1.802        | 1.003       | 3.238       | 1.970   | 0.049   |                            | 14.47           |                |
| Garzotto 2000(uva) | 61         | 1.240        | 1.057       | 1.455       | 2.639   | 0.008   |                            | 31.03           |                |

Meta Analysis

**Figure 1** Meta-analysis of univariate and multivariate data sets for predictive value of serum alkaline phosphatase level on survival time using hazard ratios.

| Study name      | Sample size | Difference in means | Standard error | Variance | Lower limit | Upper limit | Z-Value | p-Value | Difference in means and 95% CI | Relative weight | Relative weight |
|-----------------|-------------|---------------------|----------------|----------|-------------|-------------|---------|---------|-------------------------------|----------------|----------------|
| Philips 2009(uva) | 138        | -241.000            | 64.942         | 4217.430 | -368.283    | -113.717    | -3.711  | 0.000   | -241.000 to -113.717          | 13.56           |                |
| Kow 2008(uva)   | 48          | -153.500            | 57.127         | 3263.451 | -265.466    | -41.534     | -2.687  | 0.007   | -153.500 to -41.534           | 16.57           |                |
| Moore 2007(mva) | 293         | -85.000             | 33.623         | 1130.519 | -150.900    | -19.100     | -2.528  | 0.011   | -85.000 to -19.100            | 32.89           |                |
| McNeill 2007(uva) | 96         | -157.000            | 59.715         | 3565.902 | -274.040    | -39.960     | -2.629  | 0.009   | -157.000 to -39.960           | 15.48           |                |
| Chun 2005(uva)  | 35          | -135.000            | 141.503        | 20023.237 | -412.342    | 142.342     | -0.954  | 0.340   | -135.000 to 142.342           | 3.38            |                |
| Val 2002(uva)   | 40          | -252.000            | 92.936         | 8637.010 | -434.150    | -69.850     | -2.712  | 0.007   | -252.000 to -69.850           | 7.36            |                |
| Garzotto 2000(mva) | 61        | -213.000            | 74.716         | 5582.525 | -369.441    | -66.559     | -2.851  | 0.004   | -213.000 to -66.559           | 10.76           |                |

Meta Analysis

**Figure 2** Meta-analysis of univariate and multivariate data sets for predictive value of serum alkaline phosphatase level on median survival time in days.
difference in MDFI was −110 days (95 % CI: −148 to −73) (Figure 8). Subset analyses on proximal humerus in particular and humerus as a whole showed MDFIs of respectively −91 and −167 days.

Age

The papers analysing age as confounding factor all reported different age categories and used different effect outcomes. As it did not occur that more than two studies used both the same outcome type and the same age categories, it appeared impossible to run a meta-analysis on more than two studies. Therefore these data are summarized in a qualitative manner in Table 1, 2 and 3.

Survival time

The influence of age on ST reported in the eight papers used is shown in Table 1 and 2. According to Saam et al. (2011) and Phillips et al. (2009), dogs under the age of 5 showed longer MSTs compared with dogs over the age of 5. This was comparable to the study of Liptak, et al. (2006), which reported that older dogs had a significantly shorter MST. In the study of Miller et al. (2009), dogs older than 6 years showed a slightly increased HR (but with insignificant p-value) compared with younger dogs. The study of Kent et al. (2004) reported that the age under the mean age in that study was not prognostic for survival. According to Spodnick et al. (1992) dogs in the age between 7 and 10 years showed a significantly
longer MST than dogs under 7 or over 10 years old. Concerning the continuous survival data; in the paper of Selvarajah et al. (2009) age overall did not significantly influence ST. Moore et al. (2007) reported that dogs have significantly worse survival rates as age increases. Overall, most studies performed in the last decennium showed worse survival rates for dogs with increasing age compared with younger dogs.

**Disease free interval**
Contradictory data were observed for DFI (Table 3). According to the study of Sotnik et al. (2010), dogs older than 8 years showed significantly longer MDFIs compared with younger dogs. Phillips et al. (2009) on the other hand reported that dogs older than 5 showed a significantly increased HR for MDFI and significantly shorter MDFIs compared with younger dogs. Miller et al. (2009) also reported an increased HR for dogs older than 6 years, however, not significantly. Last, in the study of Kent et al. (2004) age under the mean age was prognostic for DFI.

**Discussion**
This is the first paper published in veterinary literature that compares outcomes in companion animal osteosarcoma using meta-analysis confirming the significance of three prognostic variables, including serum alkaline phosphatase, location and age in this devastating tumor.

**Serum ALP is a strong prognosticator**
SALP is most likely the strongest prognostic indicator for ST and DFI of canine OS and confirmed expectations in the veterinary literature. Bone alkaline phosphatase is a bone turnover marker measured in serum. It reflects the increased turnover associated with bone destruction or aging and various conditions affecting bone metabolism.

---

**Meta Analysis**

**Figure 5** Meta-analysis of univariate and multivariate data sets for predictive value of location of tumor (LOC) on survival time using hazard ratios.

**Figure 6** Meta-analysis of univariate data sets for predictive value of location of tumor (LOC) level on median survival time in days.
metabolism [28], such as osteosarcoma. The prognostic significance of serum total alkaline phosphatase activity for human beings with osteosarcoma has been recognized for over 30 years [29]. In most veterinary studies, the total SALP is measured. Total SALP is easily quantifiable and a routine diagnostic test in most veterinary laboratories. Total SALP, however, consists of several other isoenzymes, of which those derived from liver (LALP) and bone (BALP) represent the majority in normal dogs. A corticosteroid-induced isoenzyme (CALP) may be present in dogs with hyperadrenocorticism and dogs receiving exogenous corticosteroids [30]. The prognostic value of total SALP for human osteosarcoma is limited by its lack of specificity for tumor tissue [31,32]. The enzyme’s activity may be increased by exogenous corticosteroid administration or hyperadrenocorticism, which may cause increases in CALP, or by cholestasis which may cause increases in LALP [31]. Measuring the total SALP might therefore not always give reliable outcomes. Measuring the bone ALP (BALP) seems more logical, since in dogs with osteosarcoma, BALP is expected and proven to be elevated and more discriminant than the other isoenzymes [33]. Serum BALP activity was a direct reflection of osteoblastic activity [34] in people. Additionally, the reference range for SALP in dogs differs among various age groups [33,35] and breeds [36], which could be another factor that may influence study results. The overall meta-analysis done in this study for median ST showed a stronger significant effect on HR than the analysis on only MVA or UVA studies. This could be caused by confounding variables that may be associated with SALP, including breed variability, underlying disease processes and differences in detection methods.

| Study name | Sample size | Hazard ratio and 95% CI | Relative weight | Relative weight |
|------------|-------------|------------------------|----------------|----------------|
| Sotnik 2010 | 69 | 2.790 (1.298, 5.999) | 2.637 (0.009) | 30.61          |
| Phillips 2000 | 155 | 1.600 (1.006, 2.545) | 1.985 (0.047) | 42.67          |
| Bargman 1996 | 48 | 4.720 (1.955, 11.395) | 3.451 (0.001) | 26.72          |

0.1 0.2 0.5 1 2 5 10
Favours A  Favours B

Figure 7 Meta-analysis of multivariate data sets for predictive value of location of tumor (LOC) on median disease free interval using hazard ratios.

| Study name | Sample size | Hazard ratio and 95% CI | Relative weight | Relative weight |
|------------|-------------|------------------------|----------------|----------------|
| McHale 2001 | 50 | 4.689 (1.586, 13.090) | 7.086 (0.039) | 17.03          |
| Sotnik 2010 | 69 | 4.622 (1.767, 12.030) | 7.330 (0.039) | 10.83          |
| Phillips 2000 | 155 | 3.425 (1.636, 7.164) | 2.939 (0.039) | 26.18          |
| Kow 2009 | 67 | 2.010 (0.923, 4.356) | 0.999 (0.039) | 14.00          |
| Hille 2009 | 198 | 0.985 (0.941, 1.034) | 0.997 (0.039) | 29.19          |

-320.00  -160.00  0.00  160.00  320.00
Favours A  Favours B

Figure 8 Meta-analysis of univariate data sets for predictive value of location of tumor (LOC) on median disease free interval (in days).
Table 1 Survival data on age of dogs with osteosarcoma coded as binary data

| Study            | N   | Studied age categories (years) | MST (days) | HR (95 % CI) | p-value |
|------------------|-----|-------------------------------|------------|--------------|---------|
| Saarn 2010 (UVA) | 12  | <=5                           | 1414       | 0.49 (0.3-1.1)| 0.08    |
|                  | 53  | >5                            | 265        |              |         |
| Phillips 2009 (UVA) | 23 | <5                           | 1263       | 0.034       |         |
|                  | 132 | >5                           | 293        |              |         |
| Miller 2009 (UVA) | 3   | <6 (reference)               |            | 0.89        |         |
|                  | 73  | 6-10                          | 1.09       | 0.21-5.68   |         |
|                  | 17  | >10                           | 1.14       | 0.28-4.71   |         |
| Liptak 2006 (MVA) | 20 | Older*                        | 2.06       | 1.03-4.14   | 0.042   |
| Kent 2004 (UVA)  | 32  | <mean age**                   |            | 0.156       |         |
| Spodnick 1992 (MVA) | 162 | 7-10*** vs. <0.01            |            |             |         |
|                  |     | <7 and >10                    |            |             |         |

UVA = univariate analysis; MVA = multivariate analysis; N = number; MST = median survival time; HR = hazard ration; reference = the reference group with which the others are compared.
* MST for older dogs was significantly decreased (median age 8.3 years, range 4.5-11 years).
** Only median age was mentioned in article (8.8 years, range 2.2-16.5 years)
*** Longer survival time.

Proximal humeral location is associated with poor survival

The most common human OS sites are the femur (42 %), tibia (19 %), and humerus (10 %) [37]. The proximal humerus, despite the fact that it is not the most common site, was associated with poorer (metastasis-free) survival [38,39] in man. In this study, the (proximal) humerus was also shown to be the location with a worse prognostic outcome for canine OS. One of the reasons is the fact that tumors in this location may be observed at a later stage compared to other locations that are more clinically obvious.

The location with the best prognosis may also be of clinical relevance for both canine and human OS, however for canine OS this information was often not available. In human OS, survival of patients with primary malignant bone tumor of distal lower extremity seems to be better than that of other sites [40]. This is comparable to canine OS: in several canine studies, the radius is cited as the location with the best prognosis for ST and DFI [2,41-43].

Age may be prognostic in canine osteosarcoma

In human OS, a primary osteosarcoma in older patients showed a poorer prognosis [38,44]. A predisposing factor in middle-aged to elderly people is Paget’s disease, however. One of the most serious complications of Paget’s disease is a significant increase in the incidence of osteosarcoma [45]. Despite of the limited amount of canine OS data available for age analyses, it seemed that increasing age is an important prognostic factor for dogs with appendicular OS. Survival time may not be the most sensitive variable, however, because it can be confounded by various other medical problems that arise in older dogs with malignant bone cancer. Additional studies comparing age categories need to be conducted using more elaborate meta-analyses.

The role of adjuvant chemotherapy

Over the years, various compounds have been used in adjuvant chemotherapy protocols against canine OSA including cisplatin, carboplatin and doxorubicin. These have been used in single and in multi-agent regimes and

Table 2 Survival data on age of dogs with osteosarcoma coded as continuous data

| Study (UVA/MVA) | N   | Continuous variable | MST (days) | HR (95 % CI) | p-value |
|-----------------|-----|---------------------|------------|--------------|---------|
| Selvarajah 2009 (UVA) | 32 | Overall             | 1.137      | 0.96-1.35   | 0.147   |
| Selvarajah 2009 (MVA) | 32 | Overall             | 204        | 1.18 (0.92-1.52)| 0.202   |
| Moore 2007 (MVA)     | 303| Increasing age      | 244*       | 0.004       |         |

* MST was recalculated from months (8) to days by multiplying with 30.5.

Table 3 Disease free interval data on age of dogs with osteosarcoma coded as binary data

| Study (UVA/MVA) | N  | Studied age categories (years) | Median DFI (days) | HR (95% CI) | p-value |
|-----------------|----|-------------------------------|-------------------|-------------|---------|
| Sottnik 2010 (UVA) | 39 | <=8                           | 204               | 0.188       |         |
| Sottnik 2010 (MVA) | 30 | >8                            | 345               | 0.59        |         |
| Phillips 2009 (UVA) | 69 | >8 vs. <=8                    | 345               | 0.42 (0.21-0.85) | 0.016   |
| Phillips 2009 (MVA) | 23 | <5                            | 1035              | 0.022       |         |
| Phillips 2009 (MVA) | 132| >5                            | 241               |             |         |
| Miller 2009 (UVA)  | 3  | <6 (reference)                |                   | 0.54        |         |
|                  | 73  | 6-10                          | 1.59 (0.33-7.71)  |             |         |
|                  | 7   | >10                           | 1.21 (0.3-4.96)   |             |         |
| Kent 2004 (UVA)   | 32  | <mean                         |                   | 0.049*      |         |

UVA = univariate analysis; MVA = multivariate analysis; N = number; DFI = disease free interval; HR = hazard ration; reference = the reference group with which the others are compared.
* DFI in this paper was stated as ‘progression free survival’.

Age may be prognostic in canine osteosarcoma

In human OS, a primary osteosarcoma in older patients showed a poorer prognosis [38,44]. A predisposing factor in middle-aged to elderly people is Paget’s disease, however. One of the most serious complications of Paget’s disease is a significant increase in the incidence of osteosarcoma [45]. Despite of the limited amount of canine OS data available for age analyses, it seemed that increasing age is an important prognostic factor for dogs with appendicular OS. Survival time may not be the most sensitive variable, however, because it can be confounded by various other medical problems that arise in older dogs with malignant bone cancer. Additional studies comparing age categories need to be conducted using more elaborate meta-analyses.

The role of adjuvant chemotherapy

Over the years, various compounds have been used in adjuvant chemotherapy protocols against canine OSA including cisplatin, carboplatin and doxorubicin. These have been used in single and in multi-agent regimes and
at varying dosage and treatment interval and an obvious survival advantage of dogs receiving chemotherapy was present compared to (historic) controls [46-49]. No obvious differences in survival were observed when these treatments were compared with pre- or post-operative chemotherapy [50] and no differences in the DFI was reported for dogs treated using single- or multi-agent chemotherapeutic regimes. The prolonged, intense use of chemotherapy is often not a valid option due to adverse side effects compromising any clinical benefits and decreasing client compliance [51]. To date, even aggressive adjunctive therapy has proven ineffective in restricting all growth of metastases. Additionally, a small number of cases of canine OS that do not receive adjuvant chemotherapy do not succumb to metastatic disease once the primary tumor has been removed [52]. This finding suggests that genetic composition of both the host and tumor may be contributing to differences in the metastatic potential. In human OS, the prognosis has increased from 20 % 5-year survival in 1970 to 60 % nowadays because of the various chemotherapeutic protocols [53]. The histological response to preoperative chemotherapy was an important clinical predictor of the result of operative treatment of human osteosarcoma and was similarly important in one study by Powers et al [54]. This indicator should be used to identify patients who are at high risk for metastasis; as such patients may be candidates for more intensive or novel therapy protocols [42]. This important prognostic factor in human OS may also be a very interesting factor to further investigate in the canine OS but very few studies have reported evaluation of this variable making meta-analysis currently impossible. Meta-analyses for this factor and for different (types of) chemotherapy may be a valuable next step to see which therapies give the most optimal results for survival in canine appendicular osteosarcoma.

New insights, limitations and recommendations for prognostic studies in canine OSA

Often scientific papers only report data when they are found significant. Non-significant results are many times only cited as ‘non significant’, yet the statistical data are left out. To be able to perform a meta-analysis taking into account all relevant data both significant and non-significant outcomes are essential. Leaving out data may result in an inadequate outcome. Unfortunately, not all available papers could be used for the meta-analyses in this study, since results were not always reported in sufficient detail whereby essential data were missing (e.g. sample size, confidence interval, HR or p-value).

For future reference, data should be coded in a manner that allows comparison of various studies with comparable objectives. For instance, we observed that in some studies data were coded as continuous variables, in other studies they are coded as binary data. Therefore, the estimates of the effect size are difficult to compare. When specific factors are coded >1, one would expect them to be a negative prognostic factor. Once coded <0 it would be a protective factor. This was sometimes mixed up. For example, in the study of Phillips (2009) elevated SALP was cited as ‘negative prognostic factor’, yet the corresponding HR was 0.44. Since on the other hand following uma analysis both ST and MST for dogs with elevated SALP was shorter than for dogs with SALP within reference range, it seemed that the HR should be 1/0.44 [55]. The paper of Sottnik, et al (2010) was not completely clear whether the HR of 0.59 corresponded to the age category ≤8 (which was the correspondent category in the study or otherwise not stated clearly in the relevant Table) or ≥8 years [56]. For the meta-analysis in the current study the HR was linked to the category ≥8 years, since in the mva analysis the same category also showed a HR <1 (0.42) and the MDFIs were also longer for that specific category. Yet the range of the DFI (uma) in the category ≤8 was extremely large which could mean that the data are not completely reliable. All in all, the systematic coding of risk factors in a consequent way would be extremely helpful for future analyses.

Although many studies are performed, on account of above-mentioned reasons it remains difficult or even impossible to compare these individual studies and significantly prove that possible prognostic factors are really prognostic. Only a few studies could be used for the meta-analyses and of these studies it needs to be said that we stretched to the limit the fact that the studies itself were comparable. This is a common and unavoidable fact for diseases that are relatively infrequent, such as canine OS. Researchers should therefore be stimulated to work together in the OS field, which is not only interesting from a research point of view but also in in the One Health approach of this comparable disease between man and dog.

Conclusions

Both elevated SALP level and the (proximal) humerus as location of the primary tumor are significant negative prognostic factors for both ST and DFI in dogs with appendicular osteosarcoma. Increasing age was associated with shorter ST and DFI, however, was not statistically significant because information of this factor was available in only a limited number of papers. Multicenter, well-designed research efforts are necessary to confound the message that should be relayed to clients and patients to allow them to make an evidence-based decision in the treatment of their animal or child with this type of malignant bone tumor. Multicenter studies are only possible when researchers use the same variable definitions and show all relevant results.
Additional file

Additional file 1: Papers (55) that met the criteria for inclusion in this study [57-107]. Table S1. Studies selected for meta-analysis.

Abbreviations
OS: Osteosarcoma; SALP: Serum alkaline phosphatase; BAP: Bone alkaline phosphatase; MIST: (Median) Survival Time; MIDFI: (Median) Disease Free Interval; MF1: Metastasis free interval; RFI: Recurrence free interval; HR: Hazard ratio; UVA: Univariate; MVA: Multivariate.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
IB carried out the manuscript search, databasing the various studies, performing the meta-analysis and drafted the manuscript. GTS helped with the manuscript search and reviewed the selected candidate manuscripts. MN participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
We are grateful for the assistance of Gerrit Koop for the meta-analysis.

Author details
1Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 108, Utrecht 3584CM, The Netherlands. 2Department of Veterinary Clinical Studies, Faculty of Veterinary Medicine, University Putra Malaysia, 43400 UPM, Serdang, Malaysia. 3Department of Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 107, Utrecht 3584CL, The Netherlands.

Received: 30 December 2011 Accepted: 13 April 2012 Published: 15 May 2012

References
1. Cooley DM, Waters DJ. Skeletal neoplasms of small dogs: a retrospective study and literature review. J Am Anim Hosp Assoc 1997, 33:11–23.
2. McNeill CJ, Overley B, Shofer FS, Kent MS, Clifford CA, Samluk M, Haney S, Van Winkle TJ, Sorenmo KU. Characterization of the biological behaviour of appendicular osteosarcoma in Rottweilers and a comparison with other breeds: a review of 258 dogs. Vet Comp Oncol 2007, 5:90–98.
3. Nordin RW, Powers BE, Torgersen JL, Smith RE, Withrow SJ. Characterization of osteosarcoma cells from two sibling large-breed dogs. J Am Vet Res 1989, 50:1971–1975.
4. Ru G, Terracini B, Gluckman LT. Host related risk factors for canine osteosarcoma. Vet J 1998, 156:31–39.
5. Spodnick GJ, Berg J, Rand WM, Schellling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992, 200:995–999.
6. Boston SE, Ethhart NP, Dernell WS, Lafferty MJ, Withrow SJ. Evaluation of survival time in dogs with stage III osteosarcoma that undergo treatment: 90 cases (1985–2004). J Am Vet Med Assoc 2006, 228:1905–1908.
7. Evans LB. Osteosarcoma in a young Great Dane dog. J S Afr Vet Assoc 1993, 64:271–273.
8. Liptak JM, Dernell WS, Straw RC, Rizzo SA, Lafferty MH, Withrow SJ. Proximal radial and distal humeral osteosarcoma in 12 dogs. J Am Anim Hosp Assoc 2004, 40:461–467.
9. Dickerson ME, Page RL, LaDue TA, Hauck ML, Thrall DE, Stebbins ME, Price GS. Retrospective analysis of axial skeleton osteosarcoma in 22 large-breed dogs. J Vet Intern Med 2001, 15:270–274.
10. Hammer AS, Weeber FR, Weisbrode SE, Padgett SL. Prognostic factors in dogs with osteosarcomas of the flat or irregular bones. J Am Anim Hosp Assoc 1995, 31:321–326.
11. Hillers KR, Dernell WS, Lafferty MH, Withrow SJ, Lana SE. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). J Am Vet Med Assoc 2005, 226:1364–1367.

12. Gorman E, Barger AM, Wypij JM, Pinkerton ME. Cutaneous metastasis of primary appendicular osteosarcoma in a dog. Vet Clin Pathol 2006, 35:358–361.
13. Peremans K, Otto A, Verschooten F, Van Bree H, Dierckx R. Soft tissue metastasis of an osteosarcoma of the humerus in a four-legged patient. Eur J Nucl Med Mol Imaging 2003, 30:188.
14. Kipperstein J, Kik M, Rutteman GR, Teske E. Prognostic significance of a new histologic grading system for canine osteosarcoma. Vet Pathol 2002, 39:240–246.
15. Loukopoulos P, Robinson WF. Clinicopathological relevance of tumour grading in canine osteosarcoma. J Comp Pathol 2007, 136:65–73.
16. Brodey RS, Abt DA. Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 1976, 168:1032–1035.
17. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, LaRue SM, Ogilvie GK, Vall DM, Morrison WB. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Intern Med 1991, 5:205–210.
18. Boston SE, Duerr F, Bacon N, Larue S, Ethhart SJ. Intraoperative radiation for limb sparing of the distal aspect of the radius without transcapal plating in five dogs. Vet Surg 2007, 36:314–323.
19. Straw RC, Withrow SJ. Limb-sparing surgery versus amputation for dogs with bone tumors. Vet Clin North Am Small Anim Pract 1996, 26:135–143.
20. Dow S, Elmhøj R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposoma-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther 2005, 16:937–946.
21. Van TM, Charney SC, de Loirimier LP, Garen JD, Griffon DJ, Gordon-Evans WJ, Wypij JM. Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain. J Vet Intern Med 2009, 23:152–160.
22. Tomlin JL, Sturgeon C, Pead MJ, Muri P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000, 147:129–132.
23. Walter CJ, Dernell WS, LaRue SM, Lana SE, Lafferty MH, LaDue TA, Withrow SJ. Curative-intent radiation therapy as a treatment modality for appendicular and axial osteosarcoma: a preliminary retrospective evaluation of 14 dogs with the disease. Vet Comp Oncol 2005, 3:1–7.
24. Brater JA, van Linge JA, Grimer RJ, Scholten RJ. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009, 35:1030–1036.
25. Kim MS, Lee SY, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY, Jeon DG. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann Surg Oncol 2008, 15:906–914.
26. Owen LN. Comparative aspects of bone tumours in man and dog. Prog R Soc Med 1967, 60:1000–1310.
27. Pakos EE, Neaouchou AD, Grimer RJ, Koumourlis HD, Abudu A, Brater JA, Jey LS, Franchi A, Soccianti C, Campaconni D, Capanna R, Aparicio J, Tabone MD, Holzer G, Abdolvalah F, Funovics P, Dominikus M, Ihahn L, Berak SG, Patino-Garcia A, Sierrasemagina L, Sajan-Muran M, Garraus M, Petrelli KS, Filo RJ, Macedo CR, Alves MT, Seiwerth S, Nagarajan R, Cripe TP, Ioannidis JP. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 2009, 45:2367–2375.
28. Jenkins DK. Bone alkaline phosphatase, a serum bone turnover assay: useful in managing postmenopausal women receiving therapy to prevent or treat osteoporosis. 2010 Quidel Corporation, 217A US 9/01.
29. McNenna RJ, Schwinn CP, Soong KY, Higinbotham NL. Osteogenic Sarcoma Arising in Paget’s Disease. Cancer 1964, 17:42–66.
30. Kormer JW, HWE: Clinical enzymology. In: In: Clinical Biochemistry of Domestic Animals. 5th edition. San Diego, CA: Academic Press; 1997:303
31. Levine AM, Rosenberg SA. Alkaline phosphatase levels in osteosarcoma tissue are related to prognosis. Cancer 1979, 44:2291–2293.
32. Liu PP, Leung KS, Kunta SM, Lee KM, Fung KP. Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma. Oncology 1996, 53:275–280.
33. Ethhart N, Dernell WS, Hoffmann WE, Wiegell RM, Powers BE, Withrow SJ. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). J Am Vet Med Assoc 1998, 213:1002–1006.
34. Leung KS, Fung KP, Sher AH, Li CK, Lee KM. Plasma bone-specific alkaline phosphatase as an indicator of osteoblastic activity. J Bone Joint Surg Br 1993, 75:286–289.
35. Allen LC, Allen MJ, Breur GJ, Hoffmann WE, Richardson DC. A comparison of two techniques for the determination of serum bone-specific alkaline phosphatase activity in dogs. *J Vet Med Soc* 2006, 228:222–224.
36. Nestor DD, Hulam KM, Johnson CA, Schall W, Kaneene JB. Serum alkaline phosphatase activity in Scottish Terriers versus dogs of other breeds. *J Vet Med Med Pathol* 2000, 43:155–160.
37. Jerome TJ, Varghese M, Sankaran B, Thomas S, Thirumogal SK. Tibial chondroblastic osteosarcoma—case report. *Foot Ankle Surg* 2009, 15:33–39.
38. Cho WH, Song WS, Jeon DG, Kong KB, Kim MS, Lee JA, Yoo JY, Kim JD, Lee SY. Differential presentations, clinical courses, and survivals of osteosarcomas of the proximal humerus over other extremity locations. *Ann Surg Oncol* 2010, 17:702–708.
39. Song WS, Kong KB, Jeon DG, Cho WH, Kim MS, Lee JA, Yoo JY, Kim JD, Lee SY. Prognosis of extremity osteosarcoma in patients aged 40–60 years: a cohort/case controlled study at a single institute. *Eur J Surg Oncol* 2010, 36:483–488.
40. Yan TQ, Guo W, Yang RL, Sun X, Qu HY. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in dogs with osteosarcoma associated with short and long survival times. *Vet Comp Oncol* 2008, 6:22–28.
41. Bacon NJ, Ehrhart NP, Demell WS, Laferty M, Withrow SJ. Use of alternating administration of carboplatin and doxorubicin in dogs with microscopic metastases after amputation for appendicular osteosarcoma: 50 cases (1999–2008). *J Vet Med Soc* 2008, 232:104–1510.
42. Sami SH, Rafat AH, Hodjat P. Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor. *Saud Med J* 2008, 29:1124–1129.
43. Saam DE, Liptak JM, Stalker MJ, Chun R. Common mechanisms of osteosarcoma and Paget’s disease. *J Bone Miner Res* 1999, 14:39–44.
44. Bailey D, Erb H, Williams L, Ruslanden D, Hauk M. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. *J Vet Intern Med* 2003, 17:199–205.
45. Berg J, Weinstein MJ, Springer DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. *J Vet Med Soc* 1995, 206:1533–1560.
46. Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hahm KA, Legendre AM, Talbott JR. The frequency of micronuclei in lymphocytes of dogs with osteosarcoma: a predictive variable for tumor response during cisplatin chemotherapy. *Cancer Epidemiol Biomarkers Prev* 1996 Aug, 5(8):653–66.
47. Hahn KA, Legendre AM, Schuller HM. Amputation and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. *J Vet Pathol* 1995, 8:1123–1128.
48. Hillers KR, Demell WS, Laferty MH, et al. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). *J Vet Med Soc* 2005 Apr 15, 226(8):1364–7.
49. Kent MS, Srom A, London CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. *J Vet Intern Med* 2004, 18:540–544.
50. Khanna C, Prehn J, Hayden D, et al. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. *Clin Cancer Res* 2002 Jul, 8(7):2406–12.
51. Khanna C, Ward PA, Park J, et al. Expression of hepatocyte growth factor c-Met in canine osteosarcoma. *Vet Pathol* 2005 Jan, 42(1):114–21.
52. Bech-Nielsen S, Brodly RS, Fidler II, et al. The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma. *Eur J Cancer* 1977 Jan, 13:33–41.
53. Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987–1990). *J Am Vet Med Assoc* 1992 Jun 15, 201(12):2005–8.
54. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). *J Vet Intern Med* 1996 Mar-Apr, 10(2):76–81.
55. Miller BJ, Guth A, Burton JH, Dow SW. Decreased ratio of CD81 T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. *J Vet Intern Med* 2010, 24:1118–1123.
56. Chun R, Garrett LD, Henry C, et al. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. *J Am Anim Hosp Assoc* 2005 Dec-Nov, 41(6):382–7.
57. DiResta GR, Aiken SW, Brown HK, et al. Use of an artificial lymphatic system during carboplatin infusion to improve canine osteosarcoma blood flow and clinical response. *Ann Surg Oncol* 2007 Aug, 14(8):2411–21.
58. Erhart N, Demell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). *J Vet Med Assoc* 1998 Oct 1, 213(7):1002–6.
59. Fieten H, Spee B, Ijer R, et al. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. *Vet Pathol* 2009 Sep, 46(5):969–77.
60. Garzotto CK, Berg J, Hoffmann WE, Rand WM. Prognostic significance of serum alkaline phosphatase activity in canine appendicular osteosarcoma. *J Vet Intern Med* 2000, 14:597–592.
61. Hahn KA, Legendre AM, Talbott JR. The frequency of micronuclei in lymphocytes of dogs with osteosarcoma: a predictive variable for tumor response during cisplatin chemotherapy. *Cancer Epidemiol Biomarkers Prev* 1996 Aug, 5(8):653–66.
62. Hahn KA, Legendre AM, Schuller HM. Amputation and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. *J Vet Intern Med* 2004, 18:540–544.
63. Chun R, Garrett LD, Henry C, et al. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. *J Cancer Res Clin Oncol* 1997, 123(1):34–8.
64. Hillers KR, Demell WS, Laferty MH, et al. Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003). *J Vet Med Soc* 2005 Apr 15, 226(8):1364–7.
65. Kent MS, Srom A, London CA, et al. Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs. *J Vet Intern Med* 2004, 18:540–544.
66. Bech-Nielsen S, Brodly RS, Fidler II, et al. The effect of BCG on in vitro immune reactivity and clinical course in dogs treated surgically for osteosarcoma. *Eur J Cancer* 1977 Jan, 13:33–41.
67. Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987–1990). *J Am Vet Med Assoc* 1992 Jun 15, 201(12):2005–8.
68. Bergman PJ, MacEwen EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). *J Vet Intern Med* 1996 Mar-Apr, 10(2):76–81.
69. Miller BJ, Guth A, Burton JH, Dow SW. Decreased ratio of CD81 T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. *J Vet Intern Med* 2010, 24:1118–1123.
70. Chun R, Garrett LD, Henry C, et al. Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. *J Am Anim Hosp Assoc* 2005 Dec-Nov, 41(6):382–7.
71. DiResta GR, Aiken SW, Brown HK, et al. Use of an artificial lymphatic system during carboplatin infusion to improve canine osteosarcoma blood flow and clinical response. *Ann Surg Oncol* 2007 Aug, 14(8):2411–21.
72. Erhart N, Demell WS, Hoffmann WE, et al. Prognostic importance of alkaline phosphatase activity in serum from dogs with appendicular osteosarcoma: 75 cases (1990–1996). *J Vet Med Assoc* 1998 Oct 1, 213(7):1002–6.
73. Fieten H, Spee B, Ijer R, et al. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma. *Vet Pathol* 2009 Sep, 46(5):969–77.
80. Lascelles BD, Demrell WS, Correa MT, et al. Improved survival associated with postoperative wound infection in dogs treated with limb-salvage surgery for osteosarcoma. *Ann Surg Oncol* 2005 Dec, 12(10):1073–83.
81. Liptak JM, Demrell WS, Straw RC, et al. Proximal radial and distal humeral osteosarcoma in 12 dogs. *J Am Anim Hosp Assoc* 2004 Nov–Dec, 40(6):461–7.
82. Liptak JM, Demrell WS, Ehrhart NL, et al. Cortical allograft and endoprostheses for limb-sparing surgery in dogs with distal radial osteosarcoma: a prospective clinical comparison of two different limb-sparing techniques. *Vet Surg* 2006 Aug, 35(6):518–33.
83. MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. *J Natl Cancer Inst* 1989 Jun 21, 81(2):93–8.
84. Mauldin GN, Matus BE, Withrow SJ, Patnaik AK. Canine osteosarcoma. Treatment by amputation versus adjuvant and adjuvant chemotherapy using doxorubicin and cisplatin. *J Vet Intern Med* 1988 Oct–Dec, 2(4):177–80.
85. McMahon M, Mathie T, Stingle N, et al. Adjuvant carboplatin and gemcitabine combination chemotherapy postamputation in canine appendicular osteosarcoma. *J Vet Intern Med* 2011 May, 25(3):511–7.
86. McNeill CJ, Ovekly B, Shofer FS, et al. Characterization of the biological behaviour of appendicular osteosarcoma in Rottweilers and a comparison with other breeds: a review of 258 dogs. *Vet Comp Oncol* 2007 Jun, 5(2):90–8.
87. Mehli ML, Seguin B, Demrell WS, et al. Survival analysis of one versus two treatments of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma. *Vet Comp Oncol* 2005 Jun, 3(2):81–6.
88. Meyer JA, Dueland RT, MacEwen EG, et al. Canine osteogenic sarcoma treated by amputation and MÆR: an adverse effect of splenectomy on survival. *Cancer* 1982 Apr 15, 49(8):1613–6.
89. Miller AG, Morley PS, Rao S, et al. Anemia is associated with decreased survival time in dogs with lymphoma. *J Vet Intern Med* 2009, 23(6):116–122.
90. Moore AS, Demrell WS, Ogilvie G, et al. Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. *J Vet Intern Med 2007 Jul-Aug*, 21(4):783–90.
91. Mullins MN, Lana SE, Demrell WS, et al. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. *J Vet Intern Med 2004 Nov-Dec*, 18(6):859–65.
92. Petty JC, Lana SE, Thamm DH, et al. Glucose transporter 1 expression in canine osteosarcoma. *Vet Comp Oncol* 2008 Jun, 6(2):133–40.
93. Phillips B, Powers BE, Demrell WS, et al. Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. *J Am Anim Hosp Assoc* 2009 Jan–Feb, 45(1):33–8.
94. Powers BE, Withrow SJ, Thrall DE, et al. Percent tumor necrosis as a predictor of treatment response in canine osteosarcoma. *Cancer* 1991 Jan 1, 67(1):126–34.
95. Saarni DE, Liptak JM, Stalker MJ, Chun R. Predictors of outcome in dogs treated with adjuvant carboplatin for appendicular osteosarcoma: 65 cases (1996–2000). *J Am Vet Med Assoc* 2011 Jan 15, 238(2):195–206.
96. Selvarajah GT, Kippenstein J, van Wolfereken ME, et al. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. *Med Oncol* 2009 Sep 7, 8:72.
97. Shapiro W, Fossome TW, Kitchell BE, et al. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. *J Am Vet Med Assoc* 1988 Feb 15, 192(4):507–11.
98. Sharik AS, Allen S, Smith K, et al. Expression of Snail2 in long bone osteosarcomas correlates with tumour malignancy. *Tumour Biol* 2011 Jan 5, 32(2):515–526.
99. Sottner JL, Rao S, Lafferty MH, et al. Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. *J Vet Intern Med 2010 Nov–Dec*, 24(6):1459–44.
100. Spodnick GJ, Berg J, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). *J Am Vet Med Assoc* 1992 Apr 1, 200(7):995–9.
101. Stein TJ, Holmes KE, Muthuswamy A, et al. Characterization of β-catenin expression in canine osteosarcoma. *Vet Comp Oncol* 2011 Mar, 9(1):65–73.
102. Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for treatment of canine osteosarcoma. *J Vet Intern Med 1991 Jul-Aug*, 5(4):205–10.
103. Thamm DH, O'Brien MG, Vail DM. Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. *Vet Comp Oncol* 2008 Jun, 6(2):126–32.
104. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, and with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979–1990). *J Am Vet Med Assoc* 1992 Feb 15, 200(4):531–3.
105. Vail DM, Kurzman ID, Glavee PC, et al. STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. *Cancer Chemother Pharmacol* 2002 Aug, 50(2):131–6.
106. Withrow SJ, Thrall DE, Straw RC, et al. Intra-articular cisplatin with or without radiation in limb-sparing for canine osteosarcoma. *Cancer* 1993 Apr 15, 71(8):2484–90.
107. Withrow SJ, Liptak JM, Straw RC, et al. Biodegradable cisplatin polymer in limb-sparing surgery for canine osteosarcoma. *Ann Surg Oncol* 2004 Jul, 11(7):705–13.

Cite this article as: Boerman et al.: Prognostic factors in canine appendicular osteosarcoma – a meta-analysis. *BMC Veterinary Research* 2012 8:56.